Accelerating Discoveries Into Medicines

Our Mission

The Stanford Innovative Medicines Accelerator (IMA) seeks to accelerate the translation of Stanford research discoveries into new medicines while expanding our knowledge of human biology.

Get on the
IMA Super-highway

At the IMA, we accelerate scientific breakthroughs at Stanford and help them find the speediest path to patients. With access to the world’s most celebrated biomedical science community coupled with our experienced drug discovery team, we help fast-track the prototyping of new medicines while also enabling patient-facing studies that inform the development of these medicines.

Think of the IMA as a navigation system along a super-highway, with on-ramps and off-ramps at critical stages of drug discovery and early development.

Shaping the Future of Medicines

Along this super-highway, it is the dedicated scientists of the IMA who facilitate the transformation of Stanford’s biomedical breakthroughs into game changing medicines. These scientists include individuals with immense industrial experience and diverse domain expertise ranging from high-throughput screening and medicinal chemistry to the prototyping of protein and gene therapies and the development of informative non-clinical models of complex diseases. They also include experts in clinical investigation and regulatory affairs.

At its core, every IMA project is led by a triumvirate of the faculty innovator, a senior member of the IMA scientific team, and a project manager who collaboratively shepherd the goal- and milestone-driven project through its various stages of validation and scaling.

Unlocking Stanford’s Innovations

We are on a mission to fulfill the promise of Stanford University to be more purposeful with the knowledge we create for the greater benefit of society. To act on this mission, we identify fundamental scientific breakthroughs made by our faculty and pressure test them to see if they can be turned into impactful medicines.

Our end goal is to bring the benefits of that research outside of Stanford through partnerships with external entities such as pharmaceutical companies, life science investors, fast-growing biotechs, or even fledgling startups that are resourced to deliver these advancements to patients worldwide.

Core Team

Bruce Koch

Bruce Koch

Director, High-Throughput Screening

Christopher Carreras

Christopher Carreras

Director, Preclinical Pharmacology

Adrian Hugenmatter

Adrian Hugenmatter

Director, Protein Therapeutics

Fabrizia Urbinati

Fabrizia Urbinati

Director, Cell and Gene Therapies

Jenna Bollyky

Jenna Bollyky

Director, IMA Clinical and Translational Research Unit

Mark Smith

Mark Smith

Director, Medicinal Chemistry

Success Stories

APMAP inhibitors to enhance monoclonal antibody cancer therapies

APMAP inhibitors to enhance monoclonal antibody cancer therapies

Funding Opportunities

No results found.

Timeline

Click on a year to learn more.

2017

Our Vision / Beginnings

Planning for Stanford’s Vision commences, and university leaders begin outlining a plan to turn more Stanford discoveries into new medicines

Learn More

2020

Founded

COVID-19 Starts to Spread Globally

Long-planned and fueled by the global pandemic, the IMA launches and focuses its early efforts on addressing COVID-19

Learn More

2020

First COVID-19 Clinical Trials

The IMA launches two outpatient clinical trials in ambulatory COVID patients

Lamda Interferon
Favipiravir

2020

Small molecule therapeutics pipeline initiated

The IMA launches first non-COVID RFP focused on developing new small molecule therapeutics

2021

Protein therapeutics pipeline initiated

The IMA launches first non-COVID RFP for protein therapeutics

2021

Patient-facing studies pipeline initiated

The IMA launches first non-COVID RFP for patient-facing studies

2022

Cell and gene therapies pipeline initiated

The IMA launches first cell and gene therapies RFP

LAST

Do Not Edit